Podcast
Episode 97 — Drug Pricing: How the Drug Pricing EO Impacts FDA and Overlaps With Grassley-Led Legislation
May 2, 2025
On April 15, President Trump signed an executive order addressing prescription drug prices. The Latham team analyzes how the EO might impact FDA and dovetails with five bills recently (re-)introduced in the Senate.
The “Lowering Drug Prices by Once Again Putting Americans First” Executive Order addresses various FDA matters, such as importation from Canada and accelerated approval of generics and biosimilars. In this episode of Connected With Latham, Washington, D.C. partners Chris Schott, Ben Haas, and Bill McConagha analyze these FDA implications, and explore how the EO overlaps with five drug pricing bills championed by Senate Judiciary Committee Chairman Chuck Grassley (R-Iowa).
Listen here or subscribe via Apple Podcasts, Spotify, or anywhere else you listen to podcasts.
Also check out Chris’s interview with Life Sciences IP Review about industry impacts of the Grassley bills.
And yes, it’s back: Read our bi-weekly Drug Pricing Digest on the website or subscribe to receive future editions in your inbox.